摘要
Neoadjuvant therapy can yield clinical benefits in earlystage breast cancer with indications.The indications,treatment regimens,and efficacy of neoadjuvant therapy have been investigated,which have contributed valuable clinical evidence.[1,2]The Chinese Society of Breast Surgery convened a panel of breast disease experts to review and discuss the literature on neoadjuvant therapy for breast cancer and evaluate relevant evidence by referring to the Grading of Recommendations,Assessment,Development,and Evaluations(GRADE)system.Taking into account China’s specific circumstances,the society and participating experts developed the Clinical Practice Guidelines for Neoadjuvant Therapy for Early-stage Breast Cancer(Version 2022)to serve as a reference for breast surgeons in China.
